Peter Nash, MD
Professor of Department of Medicine
Director of Rheumatology Unit on the Sunshine Coast
University of Queensland
Queensland, Australia
Professor of Department of Medicine
Director of Rheumatology Unit on the Sunshine Coast
University of Queensland
Queensland, Australia
Related Videos
What are the risks for infection when treating RA patients with biologics?
What are the risks for infection when treating RA patients with biologics?
What metabolic or hematologic markers should we monitor in patients on IL-6 therapy?
What metabolic or hematologic markers should we monitor in patients on IL-6 therapy?
What is your assessment of the cardiovascular risk profile associated with IL-6 therapy? And the possible role of IL-6 inhibition as a mitigator of any effects related to LDL elevation?
When a suboptimal clinical response has been encountered with a traditional DMARD, what therapeutic approaches for escalating therapy are appropriate?
When a suboptimal clinical response has been encountered with TNF, do you recommend switching to a biologic with a different MoA, such as an IL-6 inhibitor or co-modulating agent?
Among the biologic agents, are there any significant efficacy or safety differentiators that prompt you to deploy one agent in preference to another, in any particular sequence?
How long of a trial using traditional DMARD therapy with methotrexate do you recommend prior to intensifying treatment with a biologic agent?
What are the strategies for individualizing treatment in patients with RA?
What are the strategies for individualizing treatment in patients with RA?
What is the precise immunopathobiologic mechanism of action for agents targeting IL-6 in the setting of RA? Are these MoAs synergistic with other MoAs? If so with which other agents should IL-6 targeting agents be used?